🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Development and Clinical Validation of Early-stage Lung Cancer Prognostic Kit

Recruitingn/aAges 20 Years - anyAllChung Shan Medical University
NCT05557474 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

Lung cancer is the leading cause of cancer mortality worldwide in spite of the advanced progresses in medication and low-dose CT screening. The early-stage lung cancer accounts for less than 50% of newly diagnosed lung cancer in Taiwan, even in stage IB patients proximately 30% still suffer from recurrence and metastasis. The International Cancer Moonshot Project recently established the first comprehensive proteogenomics profiling of early-stage lung cancer patients in East Asia, revealing a proteomics-informed classification to identify a new "late like" subtype, which can identify a subgroup of early-stage patients with worse clinicopathological features (Cell, Cover story, 2020). This study has been featured in prestigious journals (Nat Rev Clin Oncol; Cancer Discov, 2020) and led to two provisional US patents. In this proposal, taking the discovery from the Cancer Moonshot multiomi

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * Willing to sign and provide subject consent. * Male or female of age 20 or older. * Patients diagnosed with lung adenocarcinoma by tumor pathology. * Lung cancer with the pathological stage of IA/IB/II/IIIA according to the American Joint Committee on Cancer Staging Manual (8th Edition). * Complete tumor resection (R0 resection). * The East Coast Cancer Clinical Research Collaborative (ECOG) performance status was 0 or 1 at the time of grouping. * Those willing to provide tumor tissue or cytology specimens (including surgical specimens, tissue biopsy specimens, or cytology specimens), blood and body fluid specimens (for follow-up or disease recurrence, such as urine, malignant pleural effusion, ascites, pericardial fluid, etc.). Exclusion Criteria: * Not primary lung cancer patients. * Lung cancer patients whose pathological stage is not IA/IB/II/IIIA according to the American Joint Committee on Cancer Staging Manual (8th Edition) after surgery. * Patients with uncontrolled malignant tumors other than lung cancer. * Uncontrolled systemic disease (such as diabetes, hypertension, active infection, etc.) (determined by the principal investigator ) * Pregnant women. * Any condition may put the patient at serious risk, may affect the interpretation of the trial results, or may seriously interfere with the patient's participation in the trial.
💊

What it tests

  • Early-stage lung cancer prognostic kit -- ELISA
  • Early-stage lung cancer prognostic kit -- IHC
📍

Where

2 sites
Chung Shan Medical University Hospital
Taichung, Taiwan
National Taiwan University, Cancer Center
Taipei, Taiwan
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy